GLYC vs. RLMD, INCR, PDSB, COYA, NVCT, ADAG, EBS, SCTL, RZLT, and MCRB
Should you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include Relmada Therapeutics (RLMD), InterCure (INCR), PDS Biotechnology (PDSB), Coya Therapeutics (COYA), Nuvectis Pharma (NVCT), Adagene (ADAG), Emergent BioSolutions (EBS), Societal CDMO (SCTL), Rezolute (RZLT), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
GlycoMimetics (NASDAQ:GLYC) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, community ranking, risk and analyst recommendations.
GlycoMimetics has higher revenue and earnings than Relmada Therapeutics. GlycoMimetics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.
GlycoMimetics received 299 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 63.38% of users gave GlycoMimetics an outperform vote while only 41.03% of users gave Relmada Therapeutics an outperform vote.
In the previous week, GlycoMimetics had 4 more articles in the media than Relmada Therapeutics. MarketBeat recorded 4 mentions for GlycoMimetics and 0 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.00 beat GlycoMimetics' score of -0.25 indicating that Relmada Therapeutics is being referred to more favorably in the news media.
GlycoMimetics' return on equity of -73.09% beat Relmada Therapeutics' return on equity.
75.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by insiders. Comparatively, 13.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
GlycoMimetics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.
GlycoMimetics presently has a consensus price target of $10.00, indicating a potential upside of 517.28%. Relmada Therapeutics has a consensus price target of $25.00, indicating a potential upside of 577.51%. Given Relmada Therapeutics' higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than GlycoMimetics.
Summary
GlycoMimetics beats Relmada Therapeutics on 11 of the 15 factors compared between the two stocks.
Get GlycoMimetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlycoMimetics Competitors List
Related Companies and Tools
